Diagnos Laboratorium Utama PT Tbk
IDX:DGNS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
129
228
|
| Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one DGNS stock under the Base Case scenario is 319.33 IDR. Compared to the current market price of 188 IDR, Diagnos Laboratorium Utama PT Tbk is Undervalued by 41%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Diagnos Laboratorium Utama PT Tbk.
| US |
|
CVS Health Corp
NYSE:CVS
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
|
| US |
|
Cigna Corp
NYSE:CI
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
|
| US |
|
Hims & Hers Health Inc
NYSE:HIMS
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Revenue & Expenses Breakdown
Diagnos Laboratorium Utama PT Tbk
Balance Sheet Decomposition
Diagnos Laboratorium Utama PT Tbk
| Current Assets | 85.5B |
| Cash & Short-Term Investments | 4.5B |
| Receivables | 55.3B |
| Other Current Assets | 25.7B |
| Non-Current Assets | 220.2B |
| Long-Term Investments | 13B |
| PP&E | 202.1B |
| Intangibles | 1.6B |
| Other Non-Current Assets | 3.6B |
| Current Liabilities | 24.7B |
| Accounts Payable | 8.7B |
| Accrued Liabilities | 4.2B |
| Other Current Liabilities | 11.8B |
| Non-Current Liabilities | 87.5B |
| Long-Term Debt | 78.9B |
| Other Non-Current Liabilities | 8.5B |
Free Cash Flow Analysis
Diagnos Laboratorium Utama PT Tbk
| IDR | |
| Free Cash Flow | IDR |
Earnings Waterfall
Diagnos Laboratorium Utama PT Tbk
|
Revenue
|
281.3B
IDR
|
|
Cost of Revenue
|
-155.2B
IDR
|
|
Gross Profit
|
126.1B
IDR
|
|
Operating Expenses
|
-126.2B
IDR
|
|
Operating Income
|
-71.6m
IDR
|
|
Other Expenses
|
-1.8B
IDR
|
|
Net Income
|
-1.9B
IDR
|
DGNS Profitability Score
Profitability Due Diligence
Diagnos Laboratorium Utama PT Tbk's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
Score
Diagnos Laboratorium Utama PT Tbk's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
DGNS Solvency Score
Solvency Due Diligence
Diagnos Laboratorium Utama PT Tbk's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Diagnos Laboratorium Utama PT Tbk's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DGNS Price Targets Summary
Diagnos Laboratorium Utama PT Tbk
Dividends
Current shareholder yield for DGNS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one DGNS stock under the Base Case scenario is 319.33 IDR.
Compared to the current market price of 188 IDR, Diagnos Laboratorium Utama PT Tbk is Undervalued by 41%.